JP7641957B2 - Ｐａｒｐ７阻害剤としてのピリダジノン - Google Patents

Ｐａｒｐ７阻害剤としてのピリダジノン Download PDF

Info

Publication number
JP7641957B2
JP7641957B2 JP2022525496A JP2022525496A JP7641957B2 JP 7641957 B2 JP7641957 B2 JP 7641957B2 JP 2022525496 A JP2022525496 A JP 2022525496A JP 2022525496 A JP2022525496 A JP 2022525496A JP 7641957 B2 JP7641957 B2 JP 7641957B2
Authority
JP
Japan
Prior art keywords
trifluoromethyl
piperidin
oxy
oxo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501253A5 (enExample
JP2023501253A (ja
Inventor
ロバート パール，ニコラス
マリー バズビンダー，メリッサ
ウェイン カンツ，ケビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribon Therapeutics Inc
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of JP2023501253A publication Critical patent/JP2023501253A/ja
Publication of JP2023501253A5 publication Critical patent/JP2023501253A5/ja
Application granted granted Critical
Publication of JP7641957B2 publication Critical patent/JP7641957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022525496A 2019-10-30 2020-10-29 Ｐａｒｐ７阻害剤としてのピリダジノン Active JP7641957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962927934P 2019-10-30 2019-10-30
US62/927,934 2019-10-30
PCT/US2020/057831 WO2021087025A1 (en) 2019-10-30 2020-10-29 Pyridazinones as parp7 inhibitors

Publications (3)

Publication Number Publication Date
JP2023501253A JP2023501253A (ja) 2023-01-18
JP2023501253A5 JP2023501253A5 (enExample) 2023-11-02
JP7641957B2 true JP7641957B2 (ja) 2025-03-07

Family

ID=73699388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525496A Active JP7641957B2 (ja) 2019-10-30 2020-10-29 Ｐａｒｐ７阻害剤としてのピリダジノン

Country Status (13)

Country Link
US (2) US11691969B2 (enExample)
EP (1) EP4051384A1 (enExample)
JP (1) JP7641957B2 (enExample)
KR (1) KR20220109401A (enExample)
CN (1) CN114761086B (enExample)
AR (1) AR120338A1 (enExample)
AU (1) AU2020375821B2 (enExample)
CA (1) CA3159188A1 (enExample)
IL (1) IL292432B1 (enExample)
MX (1) MX2022005216A (enExample)
PH (1) PH12022551013A1 (enExample)
TW (1) TWI902715B (enExample)
WO (1) WO2021087025A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為ｐａｒｐ７抑制劑的嗒酮
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
US20240166664A1 (en) * 2021-02-03 2024-05-23 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof
EP4291560A4 (en) * 2021-02-09 2025-01-15 Jacobio Pharmaceuticals Co., Ltd. TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS
WO2022188889A1 (zh) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
CN117279917A (zh) * 2021-05-21 2023-12-22 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
WO2022247839A1 (zh) * 2021-05-25 2022-12-01 山东轩竹医药科技有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (zh) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
WO2023020479A1 (zh) * 2021-08-16 2023-02-23 重庆华森制药股份有限公司 Parp7抑制剂及其应用
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
WO2023185073A1 (zh) * 2022-04-01 2023-10-05 诺沃斯达药业(上海)有限公司 Parp7抑制剂及其用途
CN117586263B (zh) * 2022-08-09 2026-04-10 康百达（四川）生物医药科技有限公司 哌嗪衍生物及其在医药上的应用
EP4570249A4 (en) * 2022-08-09 2026-07-22 Kangbaida Sichuan Biotechnology Co Ltd USE OF A PIPERAZINE COMPOUND IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF A TUMOR
TW202416984A (zh) * 2022-08-17 2024-05-01 大陸商北京加科思新藥研發有限公司 化合物i或其鹽的固體形式
CN117164524B (zh) * 2022-09-06 2026-02-03 杭州师范大学 具有parp7/hdac双靶点抑制活性的哒嗪酮衍生物及其制备方法和应用
WO2024149231A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN121752568A (zh) * 2023-08-29 2026-03-27 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503166A (ja) 2007-11-15 2011-01-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｐａｒｐ阻害剤としてのピリダジノン誘導体
JP6942896B2 (ja) 2018-04-30 2021-09-29 ライボン・セラピューティクス・インコーポレイテッドＲｉｂｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐａｒｐ７阻害剤としてのピリダジノン

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3255293B2 (ja) 1997-09-05 2002-02-12 松下電器産業株式会社 蛍光偏光法
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
MX347085B (es) 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
RU2013150102A (ru) 2011-04-11 2015-05-20 Эббви Инк. Ингибиторы parp для лечения cipn
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為ｐａｒｐ７抑制劑的嗒酮
JP7382261B2 (ja) 2020-03-19 2023-11-16 株式会社日立製作所 情報処理装置及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503166A (ja) 2007-11-15 2011-01-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｐａｒｐ阻害剤としてのピリダジノン誘導体
JP6942896B2 (ja) 2018-04-30 2021-09-29 ライボン・セラピューティクス・インコーポレイテッドＲｉｂｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐａｒｐ７阻害剤としてのピリダジノン
JP7518049B2 (ja) 2018-04-30 2024-07-17 ライボン・セラピューティクス・インコーポレイテッド Ｐａｒｐ７阻害剤としてのピリダジノン

Also Published As

Publication number Publication date
CN114761086B (zh) 2025-07-22
EP4051384A1 (en) 2022-09-07
CN114761086A (zh) 2022-07-15
PH12022551013A1 (en) 2023-03-06
US12617782B2 (en) 2026-05-05
TWI902715B (zh) 2025-11-01
TW202128653A (zh) 2021-08-01
WO2021087025A1 (en) 2021-05-06
KR20220109401A (ko) 2022-08-04
US11691969B2 (en) 2023-07-04
MX2022005216A (es) 2022-06-02
CA3159188A1 (en) 2021-05-06
US20240034728A1 (en) 2024-02-01
IL292432A (en) 2022-06-01
JP2023501253A (ja) 2023-01-18
IL292432B1 (en) 2026-05-01
AR120338A1 (es) 2022-02-09
AU2020375821A1 (en) 2022-06-02
AU2020375821B2 (en) 2026-03-19
US20210130342A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US12617782B2 (en) Pyridazinones as PARP7 inhibitors
AU2024200566B2 (en) Pyridazinones as PARP7 inhibitors
US20250074897A1 (en) Pyridazinones as parp7 inhibitors
US9855269B2 (en) Aminoquinazoline and pyridopyrimidine derivatives
US20240199584A1 (en) Kras inhibitors
KR20220102156A (ko) Bcl6 표적화 모이어티에 연결된 e3 유비퀴틴 리가아제 결합 모이어티를 함유하는 이기능성 분자
TW202146416A (zh) 吡唑并三𠯤
CA3176957A1 (en) Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
EA049968B1 (ru) Пиридазиноны как ингибиторы parp7
HK40048232A (en) Pyridazinones as parp7 inhibitors
HK40048232B (en) Pyridazinones as parp7 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250225

R150 Certificate of patent or registration of utility model

Ref document number: 7641957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150